Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT7104 in Advanced Solid Tumors
NCT05200013Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Apr 2022
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT7104 in solid tumor (advanced stage) (6 cohorts), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity at 28 days, Adverse Events and 1 more. Started Apr 2022; status: completed.
02
Drugs
BAT7104
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05200013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200013.